Covid-19 CD40 RBDv is under clinical development by LinKinVax Europe Spas and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

GT-201 is under clinical development by Shanghai Grit Biotechnology and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

GIP/GLP-1 Coagonist III is under clinical development by Eli Lilly and Co and currently in Phase I for Cardiometabolic Disease.

Anti-PD-1/VEGF BsAb is under clinical development by 3SBio and currently in Phase II for Gynecological Cancer.

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL).

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

PrimePro is under clinical development by Thomas Advanced Medical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

TLC-6740 is under development for the treatment of insulin resistance, obesity, diabetes and nonalcoholic steatohepatitis (NASH). The drug candidate is a liver-targeted, mitochondrial protonophore ...

SLV-213 is under clinical development by Selva Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

HB-adMSC Allogeneic is under clinical development by Hope Biosciences and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.